Clinical Trial Update: Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating a chemo-immunotherapy regimen of gemcitabine, interferon-alpha 2b, and p53 SLP in platinum-resistant recurrent ovarian cancer has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Interferon-alpha-2b (interferon alfa-2b)
• p53 SLP (p53 synthetic long peptide)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Recurrent Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED